SEC Filing Summary: Entero Therapeutics, Inc. (ENTO)
Business Context and Reporting Period
This Form 8-K was filed by Entero Therapeutics, Inc. on July 8, 2025, reporting an event that occurred on July 3, 2025. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol ENTO. The filing addresses regulatory compliance status regarding the company's Annual Meeting held on June 30, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the resolution of a listing compliance issue. Nasdaq determined that the Company has regained compliance with Nasdaq Listing Rule 5620(a) (the Annual Meeting Rule) following the holding of its Annual Meeting on June 30, 2025. Consequently, the matter regarding the company's listing status is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of new risks or contingencies. The document solely confirms the closure of the prior compliance matter with Nasdaq.
Key Facts for Investor Verification
- Entero Therapeutics, Inc. has officially regained compliance with Nasdaq Listing Rule 5620(a).
- The compliance was achieved by holding the Annual Meeting on June 30, 2025.
- The Nasdaq Listing Qualifications department has closed the matter as of July 3, 2025.
- The report was signed by Richard Joel Paolone, Interim Chief Executive Officer.